Dallas, TX -- (SBWIRE) -- 02/02/2015 -- The report "Leiomyosarcoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for leiomyosarcoma. Leiomyosarcoma is a type of soft tissue sarcoma. Leiomyosarcoma is a cancerous tumor that arises from smooth muscle cells. Most people with leiomyosarcoma are over the age of 50. The exact causes of leiomyosarcomas are unknown. People with premature leiomyosarcoma often don't have any symptoms. Most leiomyosarcomas are diagnosed after a person develops symptoms. These may include a lump or swelling, abdominal discomfort or bloating, swelling or pain in any area of the body, bleeding from the vagina in women. Complete Report is Available @ http://www.rnrmarketresearch.com/leiomyosarcoma-pipeline-review-h1-2015-market-report.html .

It also reviews key players involved in the therapeutic development for leiomyosarcoma and special features on late-stage and discontinued projects. Companies discussed in this leiomyosarcoma Pipeline Review H1 2015 report include GlaxoSmithKline plc, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Mirati Therapeutics Inc., Novartis AG, Pharma Mar, S.A.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269597 . (This is a premium report priced at US$2000 for a single user License.)

Table of Contents

List of Tables
Number of Products under Development for Leiomyosarcoma, H1 2015 7
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Leiomyosarcoma - Pipeline by GlaxoSmithKline plc, H1 2015 16
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17
Leiomyosarcoma - Pipeline by Merck & Co., Inc., H1 2015 18
Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H1 2015 19
Leiomyosarcoma - Pipeline by Novartis AG, H1 2015 20
Leiomyosarcoma - Pipeline by Pharma Mar, S.A., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Leiomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 60
Leiomyosarcoma - Dormant Projects, H1 2015 83
Leiomyosarcoma - Discontinued Products, H1 2015 84

Inquiry before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269597 . (This is a premium report priced at US$2000 for a single user License.)

List of Figures

Number of Products under Development for Leiomyosarcoma, H1 2015 7
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About RnRMarketResearch
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.